CDKN2A and neoplasm: Desirable criteria are MAPK pathway gene alterations and homozygous deletion or mutation of CDKN2A and/or CDKN2B (both present in this tumour), as well as mutation of ATRX and anaplastic histological features (both not present in this tumour).